AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Statin Combined with Amlodipine Treats Primary Aldosteronism

RecruitingPhase 4Ages 18 Years - 70 YearsAllThird Military Medical University
💬

In plain words

What the trial is, and whether it could suit you

The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Clinical diagnosis of primary aldosteronism Exclusion Criteria: * Allergy to drugs in this study * Pregnancy * Severe liver and kidney dysfunction * Mental illness
💊

What it tests

  • Simvastatin combined with Amlodipine besylate
  • Simvastatin combined with Spironolactone and Amlodipine besylate.
  • Amlodipine besylate combined Spironolactone
📍

Where

1 site
No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China
Chongqing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy